



## **Annual Declaration of Interests<sup>1</sup> (DoI) form (v1, 30 June 2025)**

European Commission initiative on Breast Cancer (ECIBC)

**Please answer each of the questions below.**

**If the answer to any of the questions is "Yes"<sup>2</sup>, please complete the corresponding fields, describing the circumstances, as appropriate.**

**If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the ECIBC activities.**

**If you do not disclose relevant activities of interest for the ECIBC, your role may be revised.**

---

<sup>1</sup> According to EC's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 10, each member of an expert group has to complete a DoI form

[https://ec.europa.eu/transparency/documents-register/detail?ref=C\(2016\)3301&lang=en](https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en)

<sup>2</sup> Answering "Yes" to the questions on this form does not automatically limit your participation in the ECIBC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (*i.e.* any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

<b>Name and Surname:</b>	<b>Sabine Siesling</b>
--------------------------	------------------------

Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<b>1. Do you have current investments<sup>3</sup> in a legal entity<sup>4</sup> with an interest related to breast cancer which either:</b> <ul style="list-style-type: none"> <li>• has a value of more than 10.000 EUR, or</li> <li>• entitles you to a voting right of 5% or more?</li> </ul>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If 'yes', please specify: <ul style="list-style-type: none"> <li>• Name of entity;</li> <li>• Place;</li> <li>• Type of entity: public, private.</li> </ul>	[Please describe your role.]

<sup>3</sup> **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (*e.g.*, proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

<sup>4</sup> **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<p><b>2. Within the past 5 years, were you employed (remunerated or non-remunerated post) or have you had any other professional relationship with a legal entity or any other body, with an interest related to breast cancer?</b></p> <p><b>A. Employment</b></p>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If 'yes', please specify: <ul style="list-style-type: none"> <li>• Name of the entity;</li> <li>• Place;</li> <li>• Type of entity: public, private;</li> <li>• Received amounts for remunerated activities.</li> </ul>	[Please describe your role.]
<p><b>B. Consultancy, including advisory activities</b></p>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If 'yes', please specify: <ul style="list-style-type: none"> <li>• Name of the entity;</li> <li>• Place;</li> <li>• Type of the entity: public, private;</li> <li>• Received amounts for remunerated activities.</li> </ul>	[Please describe your role.]

Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<b>C. Non-remunerated post</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If 'ye's, please specify: <ul style="list-style-type: none"> <li>• Name of the entity;</li> <li>• Place;</li> <li>• Type of the entity: public, private;</li> </ul>	[Please describe your role.]
<b>D. Legal representation<sup>5</sup></b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If 'yes', please specify: <ul style="list-style-type: none"> <li>• Name of the entity;</li> <li>• Place;</li> <li>• Type of the entity: public, private;</li> </ul>	[Please describe your role.]

---

<sup>5</sup> **Legal representation** refers to the representation of natural or legal persons through other persons in accordance with national law. For example, the president of a company is the legal representative of that company.

Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<p><b>3. Regarding research related to breast cancer within the past 5 years:</b></p> <p><b>A. Have you been an investigator in research studies on breast cancer?</b></p>	<p>Yes <input checked="" type="checkbox"/></p> <p>No <input type="checkbox"/></p>	<p>2014-2021</p> <p>2013-2015</p> <p>2012-2015</p> <p>2016-2021</p> <p>2020-2023</p> <p>2022-onward</p> <p>Start July 2023-onward</p> <p>2024-2025</p> <p>2024-2029</p> <p>2024-2029</p>	<p>Variation in direct reconstruction after ablation in breast cancer in The Netherlands ; PI</p> <p>Netherlands Breast Cancer Project: personalized medicine and biobanking ; PI WP2</p> <p>RARECAREnet ; PI WP5</p> <p>Primary and secondary care cancer Registry (PSCCR). PI</p> <p>The impact of the Covid-19 outbreak on the diagnosis and treatment of cancer patients: lessons for the future. <i>PI</i></p> <p>Effectiveness of personalized care After treatment for non-metastasized Breast cancer based On risk of Recurrence, personal needs and risk on (late) health effects: the NABOR study. PI</p> <p>Pioneers in Health Care- optimizing a Patients-like-me dashboard</p> <p>The impact of COVID on outcome of cancer patients and the changes in care on the long time.</p> <p>SYMPHA trial (monitoring effectiveness of monitoring side effects in metastasised breast cancer patients including a FitBit)</p> <p>eChemocoach trial (monitor and triage side effects in early breast cancer).</p>	<p>Several papers and a PhD thesis</p> <p>Several papers and PhD thesis</p> <p>Papers and reports</p> <p>Several papers, one decision tool (ALERT!)</p> <p>Several papers and reports with facsheets.</p> <p>Several papers</p> <p>No publications yet</p> <p>Several papers and end report</p> <p>No publications yet</p> <p>No publications yet</p>

Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<b>B. If yes, for the aforementioned research studies, did you receive support<sup>6</sup>?</b>	Yes <input checked="" type="checkbox"/>	2014-2021	Dutch Cancer Society (€74.820)	
	No <input type="checkbox"/>	2013-2015	ZonMW (€320,321)	
	2012-2015	FP-7 collaborative Action Project		
	2016-2021	ZonMW (€233.098,-)		
	2020-onward	ZonMW (€ 499.959,-)		
	2022-2024	ZonMW (€ 1.479.390,-)		
	2024-onward	PIHC (€ 60.000,-)		
		KWF ((€ 1.480K, 900K)		

<sup>6</sup> **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).

<b>4. Do you have membership in national or international organisations<sup>7</sup>, including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies or any decision-making bodies with an interest in breast cancer?</b>	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	March 2014- now	Advisor German Ministry of Health “Zentrums für Krebsregisterdaten” at the Robert Koch-Institut, Berlin, Germany Public	To advice on use of cancer registry data
		2015- 2017	Dutch Association of Epidemiologists Member of the steering board International	Chair
		2011-2015 2011-2016	European network for Cancer Registries (ENCR) Agency of Cancer Registries (IACR), Lyon, France	Board member General secretary
		2011-now	Steering group NABON breast Cancer Audit (NBCA)	Member and projectleader from IKNL
		2012-2016	Federation of Biomedical Associations (FEDERA)	Member (on behalf of Epidemiology Association)
		Oct 2016- now	Scientific Advisory Board Evidencio : a prediction model library private	<a href="https://www.evidencio.com/">https://www.evidencio.com/</a> providing advice and guidance in the development of the Evidencio Platform and the methodologies and processes relating to the creation, us, validation and dissemination of medical prediction models.
		Jan 2018- May 2022	Member of the supervisory board of the nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA Foundation)	<a href="https://www.palga.nl/en/">https://www.palga.nl/en/</a>
	Sept 2023- ongoing	Member of the Advisory board of the Dutch Association for Epidemiologists	<a href="https://www.epidemiologie.nl/">https://www.epidemiologie.nl/</a>	

Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<b>5. Do you have intellectual property rights (IPR)<sup>8</sup> related to breast cancer?</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please specify the title of the IPR.	[Please describe the IPR.]
<b>6. Within the past 5 years:</b>				
<b>A. Have you provided any expert opinion or testimony in the field of breast cancer, for a legal entity or other body as part of a regulatory, legislative or judicial process?</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]
<b>B. Have you held an office or other position, paid or unpaid, where you represented interests or defended an opinion in the field of breast cancer?</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]

<sup>7</sup> **Organisation** refers to a governmental, international or non-profit organisation.

<sup>8</sup> **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<b>7. Do any of your immediate family members<sup>9</sup> have direct interests related to breast cancer that could undermine your independence?</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the interest.	[Please describe the interest.]
<b>8. Within the past 5 years, did you take part in other activities with interests related to breast cancer?</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please specify the title of the activity.	[Please describe the activity.]

**Notes:**

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published<sup>10</sup> before you send the DoI form to the Joint Research Centre (JRC), EC.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending an e-mail as soon as possible at: [JRC-CANCER-POLICY-SUPPORT@ec.europa.eu](mailto:JRC-CANCER-POLICY-SUPPORT@ec.europa.eu).

I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.

I agree my DoI form to be publicly available on the EC's web-hub on cancer screening and care, during the ECIBC membership<sup>11</sup>.

I am informed that my personal data are stored, processed and published by the EC in accordance with Regulation (EU) 2018/1725<sup>12</sup>.

<sup>9</sup> **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

<sup>10</sup> Personal data processing including the DoI  
<https://ec.europa.eu/dpo-register/detail/DPR-EC-00656>

<sup>11</sup> Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.

<sup>12</sup> Protection of individuals with regard to the processing of personal data

**Name and Surname:** Sabine Siesling

**Date:** 03-09-2025

**Signature**

A handwritten signature in black ink, appearing to read 'Siesling', with a long horizontal flourish extending to the left.

**Place:** Enschede

---

<https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725>